Monitor upcoming quarterly filings for any changes in cash runway or financing strategy under the new CFO. The appointment of a CFO with capital markets and M&A experience may signal preparation for fundraising or business development activity.
Price Chart
Executive Summary
Actinium Pharmaceuticals appointed Matt David, M.D. as CFO, effective October 14, 2026. Dr. David brings extensive biopharma finance and operating experience, including prior CFO and interim CEO roles at CorMedix. The appointment fills a key leadership position at a pre-revenue clinical-stage radiopharmaceutical company, but no financial guidance or material business updates were provided.
Key Facts
- Matt David, M.D., age 49, appointed CFO and principal financial officer effective October 14, 2026
- Offer letter dated September 30, 2026 provides $450,000 annual base salary, 40% target bonus, and $150,000 sign-on bonus
- Granted option to purchase 250,000 shares and 325,000 restricted stock units under 2026 Employment Inducement Award Plan
- Dr. David previously served as CFO of CorMedix Inc. (May 2020–Sep 2025) and as interim CEO (Oct 2021–May 2022)
- No financial results, guidance, or pipeline milestones disclosed in the filing
Financial Impact
CFO compensation package: $450K base salary + $150K sign-on bonus + equity grants (250K options + 325K RSUs); no revenue or financial impact disclosed
Risk Factors
- Pre-revenue clinical-stage company with no approved products and ongoing cash burn
- Equity grants to new CFO add modest dilution (575,000 shares/RSUs underlying awards)
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-109884 |
| Document: ea030854201ex99-1.htm | 0001213900-26-109884 |
| Document: 0001213900-26-109884-index-headers.html | 0001213900-26-109884 |
| Document: 0001213900-26-109884-index.html | 0001213900-26-109884 |
| Document: 0001213900-26-109884.txt | 0001213900-26-109884 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 11d ago | DEF 14A | $1.13 | awaiting T+20 | — | $1.44 (+27.43%) |
Oct 15, 2026 11d ago | 8-K | $1.13 | awaiting T+20 | — | $1.44 (+27.43%) |
Aug 14, 2026 10w ago | Press Release | $1.05 $1.25 | ▲ +19.05% | ▲ +21.03% | $1.44 (+37.14%) |
Aug 14, 2026 10w ago | 8-K | $1.05 $1.25 | ▼ −19.05% | ▼ −21.03% | $1.44 (−37.14%) |
Jun 18, 2026 18w ago | 8-K | $1.03 $0.9219 | ▲ +10.50% | ▲ +10.35% | $1.44 (−39.81%) |
May 29, 2026 21w ago | 8-K | $1.18 $0.9800 | ▲ +16.95% | ▲ +15.65% | $1.44 (−22.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers